GILD · 8-K · 20260804PR000028
Guidance / Outlook
GILEAD SCIENCES, INC. · 2026-08-04 · Importance 95 · Surprise 92 · No source text
Gilead raised 2026 product-sales guidance to $30.1 billion-$30.4 billion from $30.0 billion-$30.4 billion previously. Product sales excluding Veklury guidance increased to $29.8 billion-$30.1 billion from $29.4 billion-$29.8 billion, while Veklury guidance was reduced to approximately $300 million from approximately $600 million. GAAP diluted loss-per-share guidance was revised to $(3.75)-$(3.40) from $(3.25)-$(2.85). Non-GAAP diluted loss-per-share guidance improved to $(0.65)-$(0.30) from $(1.05)-$(0.65), with both ranges including an approximately $9.08 per-share impact from $11.1 billion of acquired IPR&D charges and related taxes.
Key facts
- Full year 2026 product sales guidance updated on August 4, 2026 to low end $30,100 million and high end $30,400 million (previously $30,000 to $30,400) source
- Full year 2026 product sales excluding Veklury guidance updated to $29,800 to $30,100 (previously $29,400 to $29,800) source
- Full year 2026 Veklury revenue guidance updated to approximately $300 (previously ~ $600) source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | +2.2% | Full year 2026 product sales excluding Veklury guidance updated to $29,800 to $30,100 (previously $29,400 to $29,800) |
| revenue | negative | probable | -1.9% | Full year 2026 Veklury revenue guidance updated to approximately $300 (previously ~ $600) |
| revenue | positive | probable | +0.6% | Full year 2026 product sales guidance updated on August 4, 2026 to low end $30,100 million and high end $30,400 million (previously… |